Prophylaxis with granulocyte colony-stimulating factor is not routinely recommended for PARP inhibitors [26], even though it was frequently used in prexasertib trials due to the high rate of G4 neutropenia [23,35,37,38]. This evidence concerns the gene PARP1 and Decreased total neutrophil count.